阿波利波蛋白E调节了阿尔茨海默病和老龄化的非APOE多基因风险评分与临床前认知功能之间的关联
Yuexuan Xu1, Zhongxuan Sun2, Erin Jonaitis3,4
1Department of Population Health Science, School of Medicine and Public Health, University of Wisconsin-Madison.
medRxiv : the preprint server for health sciences
|July 3, 2023
概括
遗传风险得分与APOE ε4等位基因相互作用,影响老年人的认知衰退. 这种相互作用在70岁左右变得明显,特别是影响记忆功能.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 临床前认知衰退有所不同,这表明除了APOE之外的遗传因素影响了疾病的进展.
- 多基因风险评分 (PRS) 可能与已知AD风险因素APOE ε4等位基相互作用,以调节认知轨迹.
研究的目的:
- 调查多基因风险得分 (PRS),APOE ε4等位基因和年龄对临床前认知功能的相互作用.
- 确定遗传风险因素是否会改变阿尔茨海默病风险人群的认知衰退.
主要方法:
- 分析了来自威斯康星州阿尔茨海默氏症预防登记处的1,190名个人的纵向数据.
- 线性混合效应模型被用来测试PRS×APOE ε4×年龄对认知措施的相互作用.
- 分析考虑了个人内部和家庭内部的相关性.
主要成果:
- 观察到具有统计学意义的PRS×APOE ε4×年龄相互作用,用于即时学习,延迟回忆和临床前阿尔茨海默氏症认知复合3分.
- 认知领域的差异,特别是记忆,在70岁左右,在具有和没有APOE ε4等位基因的个体之间出现.
- 在APOE ε4载体中,人们注意到PRS对认知的更强烈的不良影响,研究结果在一个独立的队列中复制.
结论:
- APOE ε4等位基因显著改变了多基因风险得分和认知衰退之间的关系.
- 遗传风险概况,结合APOE状态,可以提供对个体AD风险和认知衰老的更细致的理解.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220
